Journal of Substance Abuse Treatment
Volume 14, Issue 6 , Pages 529-534 , November 1997

Naltrexone pharmacotherapy for opioid dependent federal probationers

  • James W. Cornish, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to James W. Cornish, MD, Treatment Research Center, 3900 Chestnut Street, Philadelphia, PA 19104-6178.
    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • David Metzger, PhD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • George E. Woody, MD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • David Wilson, MEd

      Affiliations

    • United State Probation Office, Eastern District of Pennsylvania, Philadelphia, PA 19106 USA
    • ,
  • A.Thomas McLellan, PhD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Barry Vandergrift

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Charles P. O'Brien, MD, PhD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA

Received 26 July 1996 ,Revised 7 March 1997 ,Accepted 31 March 1997.

References 

  1. Alterman AI, McLellan AT, O'Brien CP, August DS, Snider EC, Cornish JW, et al. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. Journal of Nervous and Mental Disorders. 1994;182:157–163
  2. Brahen LS, Capone T, Heller RC, Linden SL, Landy HT, Lewis MJ. Controlled clinical study of naltrexone side effects comparing first-day doses and maintenance regimens. American Journal of Drug and Alcohol Abuse. 1978;5:235–245
  3. Brahen LS, Henderson RK, Capone T, Kordal N. Naltrexone treatment in a jail work-release program. Journal of Clinical Psychiatry. 1984;45:49–52
  4. Carroll KM, Power ME, Bryant K, Rounsaville BJ. One-year follow-up status of treatment-seeking cocaine abusers. Psychopathology and dependence severity as predictors of outcome [see comments]. Journal of Nervous and Mental Disorders. 1993;181(2):71–79
  5. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192–213
  6. Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B. Naltrexone: A clinical perspective. Journal of Clinical Psychiatry. 1984;45:25–28 (9 Pt 2)
  7. Greenstein RA, Evans BD, McLellan AT. Predictors of favorable outcome following naltrexone treatment. Drug and Alcohol Dependence. 1983;12:173–180
  8. Hollister L. Clinical evaluation of naltrexone treatment of opiate dependence: Report of the NRC Committee on clinical evaluation of narcotic antagonists. Archives of General Psychiatry. 1978;35:335–340
  9. Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: Efficacy and safety in a double-blind dosage comparison. Drug Alcohol Dependence. 1981;7:325–346
  10. Judson BA, Goldstein A. Naltrexone treatment of heroin addiction: One-year follow-up. Drug Alcohol Dependence. 1984;13:357–365
  11. Kleber HD, Kosten TR. Naltrexone induction: Psychologic and pharmacologic strategies. Journal of Clinical Psychiatry. 1984;45:29–38
  12. Lewis DC. The clinical usefulness of narcotic antagonists: Preliminary findings on the use of naltrexone. American Journal of Drug and Alcohol Abuse. 1975;2:403–415
  13. Lewis DC, Mayer J, Hersch RG, Black R. Narcotic antagonist treatment: Clinical experience with naltrexone. International Journal of the Addictions. 1978;13:961–973
  14. Ling, W, Wesson, DR. Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. Journal of Clinical Psychiatry. 1984;45:46–48
  15. Martin WR. Treatment of heroin dependence with naltrexone. Current Psychiatric Therapies. 1975;15:157–161
  16. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Archives of General Psychiatry. 1973;28:784–791
  17. O'Brien CP, Greenstein RA, Mintz J, Woody GE. Clinical experience with naltrexone. American Journal of Drug and Alcohol Abuse. 1975;2:365–377
  18. O'Brien CP, Woody GE, McLellan AT. A new tool in the treatment of impaired physicians. Philadelphia Medicine. 1986;82(11):442–446
  19. Rawson RA, Obert JL, McCann MJ, Ling W. Psychological approaches for the treatment of cocaine dependence-A neurobehavioral approach. Journal of Addictive Diseases. 1991;11(2):97–119
  20. Schecter AJ, Friedman JG, Grossman DJ. Clinical use of naltrexone (EN-1639A): Part 1: Safety and efficacy in pilot studies. American Journal of Drug and Alcohol Abuse. 1974;1:253–269
  21. Shulman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biological Psychiatry. 1994;35:935–945
  22. Tennant FS, Rawson RA, Cohen AJ, Mann A. Clinical experience with naltrexone in suburban opioid addicts. Journal of Clinical Psychiatry. 1984;45:42–45 (9 Pt 2)
  23. Washton AM, Gold MS, Pottash AC. Successful use of naltrexone in addicted physicans and business executives. Advances in Alcoholism and Substance Abuse. 1984;4(2):89–96

☆ Work supported by NIDA Grant DA05186. Thanks to the Federal Judges, U.S. Probation Officers and management staff of the Eastern District of Pennsylvania for their tremendous support and invaluable assistance. Narcan® brand naloxone, ReVia® brand naltrexone, and patient brochures describing ReVia® were generously supplied by DuPont Pharmaceuticals. Thanks also to Assunta Cuccia, Phase Four Manager, DuPont Pharmaceuticals for continuous professional support.

PII: S0740-5472(97)00020-2

Journal of Substance Abuse Treatment
Volume 14, Issue 6 , Pages 529-534 , November 1997

Article Tools